Baxter International Inc

BAX is in a Stage 2 advance with higher highs and higher lows supporting a bullish medium-term posture. Price is pulling back into the rising 9 and 20 EMAs on lighter volume, offering a favorable entry in the uptrend. Despite overbought RSI and a Bullish Exhaustion signal near resistance, the intermediate structure remains constructive, so buying now on this pullback is warranted.

• ↑Free cash flow of $76 M in Q1 vs –$221 M prior year; targeting 3× net leverage by end-2026
• ↑Q1 revenue rose 3% YoY to $2.7 B; advanced surgery sales up 10% to $304 M
• ↓Adjusted EPS fell 35% YoY to $0.36; gross margin down 500 bps to 36.8%